02-Jul-2026 15:05:45

ONESOURCE SPECIALTY PHARMA : COMPLETION OF US-FDA INSPECTION

• Routine cGMP inspection conducted by USFDA at Sterile Product Division facility in Bengaluru from June 22, 2026 to June 30, 2026. • The inspection concluded with one observation. • The company will respond to the observation to FDA within the stipulated time frame. • Stock exchanges will be informed of further developments. Impact: Neutral (Routine inspection with one observation)

Onesource Specialty Pharma Ltd

← Back to feed